French-headquartered logistics and distribution provider Bolloré Logistics has been steadily increasing its footprint in Korean life sciences in recent years – attaining international certifications to assure potential partners of their…
Click here to register and download PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: China. From the world’s ninth largest pharma market in 2007 to its second-biggest merely 12…
China’s unbridled growth has spurred a vast number of overseas Chinese to return home to seek new opportunities in their transformed homeland. Affectionately known as ‘sea turtles’ because the Chinese…
Eurasia Group’s Aditya Bhattacharji discusses the relatively modest scope of Malaysia’s recently-launched ‘MYSalam’ scheme; a healthcare programme which aims to provide coverage to the country’s bottom 40 percent of earners.…
Lydia Guo, Grace Zhao and Mendy Zhang of executive search firm Egon Zehnder outline some of the latest trends affecting the Chinese pharma sector and what they look for in…
Two leading executive recruitment specialists – DHR International’s Helen Park and Egon Zehnder’s Eugene Kim – outline the qualities they look for when hiring pharma country managers for the challenging…
Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare disease patient himself, he is responsible for bringing“International Rare Disease Day” to…
What do executive recruitment firms look for when hiring country managers for multinational pharma companies in some of the world’s most challenging markets? Eric Bouteiller and Simon Wan of Cornerstone…
Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s ambitious healthcare insurance scheme, “Modicare” and delves into some of its critical challenges and associated…
South Korean heavyweight Daewoong Pharmaceutical saw record sales in 2018, but did see a decrease in its EBITDA figures. To ensure its future profitability, the company has decided to invest…
China is planning to establish a new national medical ethics committee in the wake of the “CRISPR babies” scandal. The committee will not be limited to overseeing gene editing…
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
See our Cookie Privacy Policy Here